Erleada significantly reduces the risk of death by 51% in mCSPC patients compared to Nubeqa, without chemotherapy, over 24 months. The study used inverse probability of treatment weighting to ensure ...

Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and quality of life for patients. The FDA has approved darolutamide (Nubeqa; Bayer ...

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen deprivation therapy cuts the risk of death by 40% over 8 years, according to ...

Excess body weight, as measured by BMI, is associated with improved overall survival (OS) in men with advanced prostate cancer, particularly those with metastatic castration-resistant disease, a ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

Patients with metastatic hormone-sensitive prostate cancer had similar overall survival no matter whether metformin was added to standard of care in a randomized trial. Metformin use was associated ...

CNN — (CNN) — President Joe Biden’s diagnosis of metastatic prostate cancer has understandably raised concerns and questions: How long has he had cancer, how will he be treated, and what is his ...

Prostate cancer has four stages, which describe how advanced the cancer is and how far it has spread throughout your body. Knowing the stage of your cancer can help you and your healthcare team ...